Cerebrospinal fluid neurochemistry in the myoclonic subtype of Alzheimer's disease

Jeffrey Kaye, C. May, J. R. Atack, E. Daly, D. L. Sweeney, M. F. Beal, S. Kaufman, S. Milstien, R. P. Friedland, S. I. Rapoport

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Monoamine metabolites, biopterin, acetylcholinesterase (AChE) activity, and somatostatin-like immunoreactivity (SLI) were determined in the lumbar cerebrospinal fluid (CSF) of 24 patients with dementia of the Alzheimer type (DAT) without myoclonus or extrapyramidal signs, in 8 patients with DAT and myoclonus, and in 14 age-matched healthy control subjects. In patients with DAT with myoclonus as compared with both DAT patients without myoclonus and control subjects, the concentrations of homovanillic acid and biopterine were significantly decreased. 5-Hydroxyindoleacetic acid was significantly lower in patients with myoclonic DAT as compared to patients with nonmyoclonic DAT, but not significantly lower then in control subject. CSF AChE and SLI were significantly reduced in patients with DAT with or without myoclonus, as compared with control subjects, but AChE and SLI were not significantly different between dementia groups. These results suggest that DAT patients with myoclonus represent a distinct clinical and neurochemcial DAT subtype.

Original languageEnglish (US)
Pages (from-to)647-650
Number of pages4
JournalAnnals of Neurology
Volume24
Issue number5
StatePublished - 1988
Externally publishedYes

Fingerprint

Neurochemistry
Cerebrospinal Fluid
Alzheimer Disease
Myoclonus
Acetylcholinesterase
Biopterin
Homovanillic Acid
Hydroxyindoleacetic Acid
Dementia
Healthy Volunteers

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Kaye, J., May, C., Atack, J. R., Daly, E., Sweeney, D. L., Beal, M. F., ... Rapoport, S. I. (1988). Cerebrospinal fluid neurochemistry in the myoclonic subtype of Alzheimer's disease. Annals of Neurology, 24(5), 647-650.

Cerebrospinal fluid neurochemistry in the myoclonic subtype of Alzheimer's disease. / Kaye, Jeffrey; May, C.; Atack, J. R.; Daly, E.; Sweeney, D. L.; Beal, M. F.; Kaufman, S.; Milstien, S.; Friedland, R. P.; Rapoport, S. I.

In: Annals of Neurology, Vol. 24, No. 5, 1988, p. 647-650.

Research output: Contribution to journalArticle

Kaye, J, May, C, Atack, JR, Daly, E, Sweeney, DL, Beal, MF, Kaufman, S, Milstien, S, Friedland, RP & Rapoport, SI 1988, 'Cerebrospinal fluid neurochemistry in the myoclonic subtype of Alzheimer's disease', Annals of Neurology, vol. 24, no. 5, pp. 647-650.
Kaye J, May C, Atack JR, Daly E, Sweeney DL, Beal MF et al. Cerebrospinal fluid neurochemistry in the myoclonic subtype of Alzheimer's disease. Annals of Neurology. 1988;24(5):647-650.
Kaye, Jeffrey ; May, C. ; Atack, J. R. ; Daly, E. ; Sweeney, D. L. ; Beal, M. F. ; Kaufman, S. ; Milstien, S. ; Friedland, R. P. ; Rapoport, S. I. / Cerebrospinal fluid neurochemistry in the myoclonic subtype of Alzheimer's disease. In: Annals of Neurology. 1988 ; Vol. 24, No. 5. pp. 647-650.
@article{ca8e24caf731445ba00801e1419d5253,
title = "Cerebrospinal fluid neurochemistry in the myoclonic subtype of Alzheimer's disease",
abstract = "Monoamine metabolites, biopterin, acetylcholinesterase (AChE) activity, and somatostatin-like immunoreactivity (SLI) were determined in the lumbar cerebrospinal fluid (CSF) of 24 patients with dementia of the Alzheimer type (DAT) without myoclonus or extrapyramidal signs, in 8 patients with DAT and myoclonus, and in 14 age-matched healthy control subjects. In patients with DAT with myoclonus as compared with both DAT patients without myoclonus and control subjects, the concentrations of homovanillic acid and biopterine were significantly decreased. 5-Hydroxyindoleacetic acid was significantly lower in patients with myoclonic DAT as compared to patients with nonmyoclonic DAT, but not significantly lower then in control subject. CSF AChE and SLI were significantly reduced in patients with DAT with or without myoclonus, as compared with control subjects, but AChE and SLI were not significantly different between dementia groups. These results suggest that DAT patients with myoclonus represent a distinct clinical and neurochemcial DAT subtype.",
author = "Jeffrey Kaye and C. May and Atack, {J. R.} and E. Daly and Sweeney, {D. L.} and Beal, {M. F.} and S. Kaufman and S. Milstien and Friedland, {R. P.} and Rapoport, {S. I.}",
year = "1988",
language = "English (US)",
volume = "24",
pages = "647--650",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Cerebrospinal fluid neurochemistry in the myoclonic subtype of Alzheimer's disease

AU - Kaye, Jeffrey

AU - May, C.

AU - Atack, J. R.

AU - Daly, E.

AU - Sweeney, D. L.

AU - Beal, M. F.

AU - Kaufman, S.

AU - Milstien, S.

AU - Friedland, R. P.

AU - Rapoport, S. I.

PY - 1988

Y1 - 1988

N2 - Monoamine metabolites, biopterin, acetylcholinesterase (AChE) activity, and somatostatin-like immunoreactivity (SLI) were determined in the lumbar cerebrospinal fluid (CSF) of 24 patients with dementia of the Alzheimer type (DAT) without myoclonus or extrapyramidal signs, in 8 patients with DAT and myoclonus, and in 14 age-matched healthy control subjects. In patients with DAT with myoclonus as compared with both DAT patients without myoclonus and control subjects, the concentrations of homovanillic acid and biopterine were significantly decreased. 5-Hydroxyindoleacetic acid was significantly lower in patients with myoclonic DAT as compared to patients with nonmyoclonic DAT, but not significantly lower then in control subject. CSF AChE and SLI were significantly reduced in patients with DAT with or without myoclonus, as compared with control subjects, but AChE and SLI were not significantly different between dementia groups. These results suggest that DAT patients with myoclonus represent a distinct clinical and neurochemcial DAT subtype.

AB - Monoamine metabolites, biopterin, acetylcholinesterase (AChE) activity, and somatostatin-like immunoreactivity (SLI) were determined in the lumbar cerebrospinal fluid (CSF) of 24 patients with dementia of the Alzheimer type (DAT) without myoclonus or extrapyramidal signs, in 8 patients with DAT and myoclonus, and in 14 age-matched healthy control subjects. In patients with DAT with myoclonus as compared with both DAT patients without myoclonus and control subjects, the concentrations of homovanillic acid and biopterine were significantly decreased. 5-Hydroxyindoleacetic acid was significantly lower in patients with myoclonic DAT as compared to patients with nonmyoclonic DAT, but not significantly lower then in control subject. CSF AChE and SLI were significantly reduced in patients with DAT with or without myoclonus, as compared with control subjects, but AChE and SLI were not significantly different between dementia groups. These results suggest that DAT patients with myoclonus represent a distinct clinical and neurochemcial DAT subtype.

UR - http://www.scopus.com/inward/record.url?scp=0023769962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023769962&partnerID=8YFLogxK

M3 - Article

C2 - 2462403

AN - SCOPUS:0023769962

VL - 24

SP - 647

EP - 650

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 5

ER -